A phase II, proof of concept study to evaluate the safety and efficacy of Trabodenoson in patients with optic neuropathies and degenerative retinal diseases.

Trial Profile

A phase II, proof of concept study to evaluate the safety and efficacy of Trabodenoson in patients with optic neuropathies and degenerative retinal diseases.

Planning
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2015

At a glance

  • Drugs Trabodenoson (Primary)
  • Indications Optic nerve disorders; Retinal degeneration
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Most Recent Events

    • 31 Mar 2015 Inotek Pharmaceuticals expects to initiate this study in the second half of 2015, according to the company SEC filing report 10-K 2014.
    • 31 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top